Lindbrook Capital LLC Sells 148 Shares of Becton, Dickinson and Company (NYSE:BDX)

Lindbrook Capital LLC decreased its stake in Becton, Dickinson and Company (NYSE:BDX) by 13.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 920 shares of the medical instruments supplier’s stock after selling 148 shares during the period. Lindbrook Capital LLC’s holdings in Becton, Dickinson and Company were worth $209,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Bank of Jackson Hole Trust bought a new stake in Becton, Dickinson and Company in the fourth quarter worth about $25,000. Sierra Ocean LLC bought a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. Ashton Thomas Securities LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $33,000. Tompkins Financial Corp raised its position in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the period. Finally, Kennebec Savings Bank bought a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $46,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $229.51 on Friday. The company has a 50 day moving average of $232.98 and a 200 day moving average of $232.73. The stock has a market cap of $65.90 billion, a P/E ratio of 38.12, a P/E/G ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has approved a share buyback program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio is presently 69.10%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the transaction, the director now owns 36,033 shares of the company’s stock, valued at $8,215,163.67. The trade was a 1.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,061 shares of company stock valued at $1,379,521 in the last quarter. Corporate insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

BDX has been the topic of several research reports. Barclays boosted their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Piper Sandler boosted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Buy” and an average price target of $278.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.